Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma

被引：3
|
作者：
Ghatalia, Pooja [1 ]
Plimack, Elizabeth R. [1 ]
机构：
[1] Fox Chase Canc Ctr, Dept Hematol & Oncol, Philadelphia, PA 19111 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2023年 / 20卷 / 12期
关键词：
CISPLATIN; CHEMOTHERAPY; CANCER; UNFIT;
D O I：
10.1038/s41571-023-00814-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Following the recent FDA Accelerated Approval of enfortumab vedotin (EV) plus pembrolizumab for patients with advanced-stage urothelial carcinoma who are cisplatin-ineligible, herein we highlight key clinical outcomes with this combination based on results from Cohort K of the pivotal phase Ib/II EV-103 trial. We also discuss treatment sequencing, de-escalation strategies and toxicity management as EV-pembrolizumab becomes widely used in clinical practice.
引用
收藏
页码：818 / 819
页数：2
相关论文
共 50 条
  • [1] Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma
    Pooja Ghatalia
    Elizabeth R. Plimack
    Nature Reviews Clinical Oncology, 2023, 20 : 818 - 819
  • [2] Pembrolizumab plus enfortumab vedotin in urothelial cancer
    Santoni, Matteo
    Takeshita, Hideki
    Massari, Francesco
    Bamias, Aristotelis
    Cerbone, Linda
    Fiala, Ondrej
    Mollica, Veronica
    Buti, Sebastiano
    Santoni, Angela
    Bellmunt, Joaquim
    NATURE REVIEWS UROLOGY, 2024, 21 (07) : 387 - 388
  • [3] Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Milowsky, Matthew, I
    Friedlander, Terence W.
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Srinivas, Sandy
    Merchan, Jaime R.
    McKay, Rana R.
    Petrylak, Daniel P.
    Sasse, Carolyn
    Moreno, Blanca Homet
    Yu, Yao
    Carret, Anne-Sophie
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (01) : 22 - +
  • [4] Enfortumab Vedotin in Advanced Urothelial Carcinoma
    Petrylak, Daniel P.
    Powles, Thomas
    Rosenberg, Jonathan E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (01): : 93 - 94
  • [5] Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Powles, T.
    Valderrama, B. P.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano, D.
    Fornarini, G.
    Li, J. R.
    Guemues, M.
    Mar, N.
    Loriot, Y.
    Flechon, A.
    Duran, I
    Drakaki, A.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10): : 875 - 888
  • [6] FDA OKs Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (02):
  • [7] EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
    Hoimes, C. J.
    Rosenberg, J. E.
    Srinivas, S.
    Petrylak, D. P.
    Milowsky, M.
    Merchan, J. R.
    Bilen, M. A.
    Gupta, S.
    Carret, A-S.
    Yuan, N.
    Melhem-Bertrandt, A.
    Flaig, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 356 - 356
  • [8] Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma
    Santoni, Matteo
    Rizzo, Alessandro
    Massari, Francesco
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2025,
  • [9] Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Catalano, Martina
    Santoni, Matteo
    Roviello, Giandomenico
    EUROPEAN UROLOGY, 2024, 86 (03) : 283 - 283
  • [10] Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer
    Sternschuss, Michal
    Rosenberg, Jonathan E.
    FUTURE ONCOLOGY, 2025,
12345